TMPRSS4作为实体瘤一种新出现的潜在不良预后因素：一项系统评价和荟萃分析。
TMPRSS4 as an emerging potential poor prognostic factor for solid tumors: A systematic review and meta-analysis.
作者信息
Zeng Ping, Zhang Peng, Zhou Li-Na, Tang Min, Shen Yi-Xin, Jin Jun, Zhu Ya-Qun, Chen Min-Bin
机构信息
Department of Radiotherapy and Oncology, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu Province, China.
Department of Orthopedics, The Second Affiliated Hospital of Soochow University, Suzhou, China.
出版信息
Oncotarget. 2016 Nov 15;7(46):76327-76336. doi: 10.18632/oncotarget.10153.
Recent studies have investigated the potential prognostic value of the transmembrane protease serine 4 (TMPRSS4) in various solid tumors. Yet, the results are inconclusive. Here, we performed this meta-analysis to clarify this issue. Relevant articles were identified by searching PubMed, Web of Science and Embase databases. The primary outcome endpoints were patients' overall survival (OS) and time to tumor progression (TTP). Twelve studies involving 1,955 participants were included. We showed that high TMPRSS4 expression in tumor tissues was significantly associated with patients' poor OS (pooled HR = 2.981, 95% CI = 2.296-3.869, P < 0.001) and short TTP (pooled HR = 2.456, 95% CI = 1.744-3.458, P < 0.001). A subgroup analysis revealed that the association between TMPRSS4 and the outcome endpoints (OS or TTP) was also significant within China region. We conclude that TMPRSS4 overexpression in solid tumors is associated with patients' poor prognosis. TMPRSS4 could be a valuable prognosis biomarker or a promising therapeutic target of solid tumor.
近期研究探讨了跨膜蛋白酶丝氨酸4（TMPRSS4）在多种实体瘤中的潜在预后价值。然而，结果尚无定论。在此，我们进行了这项荟萃分析以阐明该问题。通过检索PubMed、科学网和Embase数据库确定相关文章。主要结局终点为患者的总生存期（OS）和肿瘤进展时间（TTP）。纳入了12项涉及1955名参与者的研究。我们发现肿瘤组织中TMPRSS4高表达与患者较差的OS（合并风险比[HR]=2.981，95%置信区间[CI]=2.296 - 3.869，P<0.001）和较短的TTP（合并HR = 2.456，95%CI = 1.744 - 3.458，P<0.001）显著相关。亚组分析显示，在中国地区，TMPRSS4与结局终点（OS或TTP）之间的关联也很显著。我们得出结论，实体瘤中TMPRSS4过表达与患者预后不良相关。TMPRSS4可能是实体瘤有价值的预后生物标志物或有前景的治疗靶点。
Zotero 插件